Filtricine
John Chant is the CEO at Filtricine. Previously, John was the Interim Chief Operations Officer at CG Oncology. John holds a Ph.D. in Genetics from the University of California, San Francisco.
Filtricine
Filtricine is a clinical-stage biotech company. Filtricine is developing a proprietary targeted nutrients deprivation (TND) technology to help patients living with cancer manage their diseases.